Chuck, Thank morning, you, and good everyone.
as milestones my I business will discuss the quarter first pipeline. recent well performance our During as remarks, from
with every about to goes I few in this lives. have challenges saying find everyone. posed solution. public and time The the Pfizer's our almost and by for is a role that unprecedented However, impacted COVID-XX without extraordinarily, It pandemic aspect health difficult of helping want start an COVID-XX thoughts
As dual. in largest one of biopharmaceuticals is the role this crisis world's companies, our
of and wellbeing one the and patients to vaccines around medicines our continuous hand, the the course. our safety On we while of are the focused colleagues maintaining supply globe, protecting of on all
contribute solutions this are expertise, and and Pfizer our outside other medical capital hand, within to we help to to On with working both experts, the pandemic. resources bring potential
front. doing of on examples Let me few share what this we a are
without I'm supply related and the our on the pleased manufacturing and hospitals team to expected distribution the our sites global operational, an that ever. more supply supply happening job, has vaccines disruptions. medicines With significant of and Pfizer outstanding critical increase, globe channels than done keeping now the say burden around to is continued
institutions potential the with finding approaches leave develop made We prevent to unturned have to we In terms and we to and are for COVID-XX. medical collaborating on solutions fronts. novel multiple aim of stone no treat pandemic, academic industry partners advances and
candidates the recently BioNTech into infection. regulatory authority approval the has collaboration first German potential Pfizer and trial to first-in-class Last we and patient have to the prevention, clinical coronavirus aimed COVID-XX announced entered Paul-Ehrlich-Institut co-develop been company, first received agreement a already vaccine at biotech German we commence Regarding mRNA-based global vaccine program preventing in that from week, the for our the Germany COVID-XX dosed.
plan also bring the work U.S. covered We a to worldwide, BioNTech excluding and vaccine Pfizer also to to and conduct course, subject BioNTech collaboration, successful to which separate trials is of upon shortly. approvals. expected development the through market will in China, regulatory which approval, regulatory already is jointly
potentially obtain We development project. working plan scale accelerate by at and risk doses XXXX. I of then on successful the in capacity want potential we end is the to event program produce and to millions manufacture thank millions of companies at XXXX hundreds everyone in vaccine the doses ability, this regulatory in rapidly of to to both of approval to the of
inhibitor against SARS-CoV-X. treatment, lead activity is antiviral know protease potential molecule a SARS-CoV-X potent now the Regarding we XC-like confirmed our very the with of
year. working to discussions antiviral the We over also ahead a activity formulation while clinical of testing are additional the invested in clinic for understanding IV accelerating the or regulatory month on of clinical studies September accelerate administration. as and potential undertaking towards antiviral early materials ago, We August and commencing this
in of novel companies patients regulatory they medicines with provide have the COVID-XX working for are several experience small to that to and promising continue Pfizer investigation also we on We COVID-XX. subject therapies. biotech our clinical research And projects
could want that publicly potential I'm against vaccines all end this the into treatments colleagues, win the working and night that late who science are an will to battle and COVID-XX. end, to At often find confident the our I bring thank R&D tirelessly to pandemic.
for turn Now, and to both, first quarter. quarter. me during headwinds to the let our Obviously, experienced results COVID-XX related we this tailwind
in one were the in our many offices. On hand, not to physicians sales their detail representatives able regions the
tests, offices patient In expected new addition, negatively at doctors’ requiring impact to March, physician-administered the the end of beginning quarter which second of visits XXXX. to diagnostic declined is conditions beginning significantly in diagnosis of
an we Eliquis. reflecting On and of for in levels as stronger ongoing well puts uptick increasing that hospital utilized in mechanically to XXXX products portfolio due in in our our resulted incubation COVID-XX treatment sterile these XXXX, as first In our in patients. the usual unit and of and the Pfizer's total, demand other large an of saw certain demand injectable for other some revenues, hand, primarily than quarter inventory increased part X% ventilated we business in benefit of net first medicines, a the anti-infective only wholesaler hospital estimate biopharma takes for to quarter products
factors, revenue half XXXX. Pfizer quarterly which Group, will Biopharmaceuticals transaction these in by performance be the growth closing of the of of Upjohn we in following the highlighted delivered anticipated that our face strong the the business overall, In second XX% remains operational
XXXX.The completion our venture in Norvasc three total U.S. will impacts quarter. expanded the expected business, declines procurement removed December Lyrica, from XXXX ‘XX to from China third loss-of-exclusivity Lipitor in revenue due and events. of expenses saw volume-based program, this implemented begin annualize for the which in consumer both Consumer negatively with the initially the recording to transaction revenue XXst July and of the which by Healthcare and and was and March Lyrica GSK, also The of company We impacted in nationwide in July joint
by Vyndaqel/Vyndamax, well Biopharmaceutical drivers. growth Eliquis, and and growth growth strong The include operational again in emerging markets. primarily performances as Inlyta, our outstanding Xtandi, from driven Group's These was Ibrance key as XX%
gains. increased and operationally XX% during this U.S., CDK in growth XX% pressures particularly strong continued to market the Global revenues In up was strong, to The business in increased quarter. billion operationally, year-ago Ibrance to and revenue quarter, the Our retained by share markets it $X.X strong compared leadership quarter. CDK class, grew led XX% was in oncology the XX% position volume the EU-X delivered This volumes markets. offset due markets. volume growth pricing the emerging by international Ibrance
As a growth U.S. the X%. was result, operational revenue outside
prostate when corporate. totaled For growth reached with overall the royalty for prostate ex-U.S. were Xtandi, during advanced expansion with alliance our And from market million. XX% in Demand all-time quarter U.S. in high leader metastatic castration-sensitive revenues and sales, Xtandi cancer, hormone $XXX into therapy XX% prostate castrate-resistant an class prescriptions share is up cancer. in novel cancer the market total to due in the solid the growth. income combined
We the launch the early with for impact are Xtandi metastatic castration-sensitive of U.S. pleased the prostate in of cancer
types only the three FDA the prostate distinct oral of is treatment and first in approved by Xtandi cancer.
Array lead to make pleased impact with adult lives Array for metastatic after a colorectal mutation potential this cancer with to Braftovi, our the acquisition by asset, are those the related with meaningful And the treatment Biopharma, in approval doubling with disease. cetuximab believe of the living of prior on Braftovi We BRAF has of a we the of therapy. combination the FDA’s patients
Eliquis several gains. by fibrillation This to up growth anticoagulant we adoption revenue was well. other $X.X driven XX% primarily oncology, continued perform to billion. performances. of in well market as global strong product was Pfizer had non-valvular oral operationally as share Beyond increased continued the share atrial
Additionally, lower U.S. growth was net buying price. related favorably offset by wholesaler COVID-XX a by impacted patterns, partially
in Vyndamax Vyndaqel to business, at in continued breakthrough our in revenue these the Overall, performance. and quarter. $XXX rare million diseases contributed first Looking strong U.S. U.S. the show medicines
have disease prior compared to of only rate XX% in the more launch. awareness than X,XXX to more XX,XXX received the and patients more X,XXX prescription, X% than have drive estimated the Our to been At helped the the efforts first X% have quarter, than the quarter, diagnosed, drug. patients with received diagnosis end patients
assistance quarter, the are taking patients of the was the number These estimate through numbers our patient approximately Vyndaqel no X,XXX. programs. For patients we at include the in drug who cost receiving average U.S.
for a approval slowdown of in orders, as April offices visiting And fewer including in we of are we new patients markets tests. in of a ATTR seeing treatment are Europe, received have we the doctor's result in In two diagnosis scintigraphy stay-at-home Germany. as Vyndaqel said, already launched for February. or cardiomyopathy That consultations,
of X% in quarter primarily the reflecting from recent were indication operationally as million. the to U.S. rheumatoid the the up well Xeljanz outside XX% launch revenue up colitis in developed markets. ulcerative $XXX arthritis, in as Revenues continued Global operationally, were certain uptake
X%. commercial in to in volume demand continued levels U.S., reflected than second Xeljanz approved higher a in signed inventory lower restored revenues all This levels wholesaler the from consistently by during In April early well indications, were were across as Wholesaler Pfizer’s XXXX XXXX, remained Xeljanz contracts demand normal more has as to net price quarter due down temporary offset rebating of underlying as inventory lowering levels strong. first for strong XXXX. quarter
operational including Prevnar the in timing purchases up emerging reflecting markets, continued of and with government Russia pediatric overall internationally, the Global Turkey. operationally for XX% in $X.XX impact growth were to uptake billion XX indications China certain primarily and revenues associated pediatric X% favorable with
XX%, periodic associated In timing with reflecting the the indication, government the primarily U.S., down purchases compared unfavorable revenues quarter. of for year the were with impact previous
portfolio. injectables sterile our at Looking
in impact recovery manufacturing positive on Our top-line the is having U.S. the a
and continue these baseline and sterile invest performance. quarter to sequentially of XXX% global Pfizer critical completed cases, of of Of certain the in pandemic, XX a have to We this baseline XX% portfolio remediation March grew injectable to medicines in quarter, modernization exceeded the more In demand. revenue supply XXX. to in X% In COVID-XX up necessary demand note, response fourth first portfolio, Pfizer operationally than more sustain of most increasing than and XXXX. compared due XX our to from to supported XXX to increased demand from our shipped
portfolio stock than is more today. XX% injectables of in Additionally, our
in performance to was XX%, portfolio Inflectra, thanks demand systems, global in of Retacrit quarter. largely biosimilars due million by erosion. the U.S., increase XX% with open strong and the in a price grew driven growth to continued increased was The offset $XXX partially to steady Our operationally by which up progress
we impact the therapeutic We in by launched three the our also engagements negative monoclonal payers we where of Inflectra had not And we few providers that and seen have contracting months. encouraged the are the innovator past with oncology launch. biosimilars U.S. seen by the exclusionary companies antibody with have initial over
nationwide were revenues The XXXX. by in Upjohn beginning began Norvasc, declined and As the billion. generic was from China for July expected, in our anticipated XXXX revenue declines initially Lyrica Lipitor the XX% were due previous down significant December value-based volume for the business. the declines in quarter March U.S. expanded to for primarily XXXX. in in operational, that driven XX% business for Upjohn by which in competition $X primarily decline guidance with program, resulting procurement primarily consistent expected of and was operationally implemented declines our to multi-source These driven the Upjohn
Regarding Upjohn’s attractive. Mylan, industrial combination continues with logic to be the very
the pushed with all to due deal change mostly commitment pre-closing activities XXXX, out we and we initiatives. of administrative delays our is COVID-XX, While expected the second transaction, continue in there close to no of half and to to the forward timing the to related move
week, proposed certain to approved medicines. transaction of Last European generic the Mylan's Commission of the divestment subject
Turning now to R&D.
we licensed call from We with Phase our safety milestones. XX-valent and areas. it of a demonstrated on XX vaccines, pneumococcal patients we adults in Pfizer's Since adult to with potential a FDA earnings expect the pneumococcal with seen and file older. significant immunogenicity results continue age top-line years XXth, fourth the X are vaccine our last vaccine The to quarter excited study has XXXX. we the range announced making and deliver profile We January therapeutic conjugate or in to early pneumococcal progress be some a exciting to comparable across candidate benefits of XX-valent indication have the of to pipeline of
is positive to this projected Phase encouraged and read about forward Phase favorable -- discussing We months. data And which maternal out tolerability data with potential announced with within our preliminary we’ll look X a had we And X few recent safety. with are RSV regulators. start a vaccine,
and endpoint, third topical on arm. with We to the control therapy, met patients announced dupilumab superior and safety in core endpoints. clinically key both In the its by arm efficacy in secondary results XXX the who with was adults background of active positive moderate arm trial of abrocitinib were in which significant Phase atopic received top-line abrocitinib from dupilumab topical background dermatitis, a reduction milligram of abrocitinib. severe X included to therapy The plus week primary a also an treated of study, proportion two the itch statistically the evaluated
milligram significantly not at abrocitinib higher two. numerically XXX statistically was week than higher but arm the dupilumab While
the regulatory later with data, FDA, positive the planned mono-therapy clinical These starting other for support along will with results filings, trials year. from this
for the tanezumab FDA for at March and review filing Our in EMA. accepted was both,
with are severe approval the X.X pursuing patients milligram analgesics. due failed osteoarthritis, who chronic for have to in pain We administered to subcutaneously moderate prior dose
a year In December. the U.S., FDA committee is we advisory year. regulators the meeting decision from decision expect in and A later an the this from expected next EU
Our ACC/DGATX study indications, towards results two license Phase meeting upcoming shared severe, and achieved study its oligonucleotide positive and the with combination will and that in primary secondary successfully for project cardiovascular X The endpoint focus ANGPTLX from reduction. advanced be program risk hypertriglyceridemia proof the endpoints. antisense concluded inhibitor at Phase concept the NASH. on has Phase Xb part has multiple Data of X/Xa Congress. the an program, of The
Preliminary results to of gene XXXX, Duchenne our start the and dosing study Xb second to patients course. X of begin the Phase support continuation Phase approvals, therapy subject in in dystrophy is of anticipated which the regulatory muscular program, of half trial a the
patients current The the need urgent pandemic, trial these of the Xb despite COVID-XX their because continues families. of Phase and
will We Gene Society and American more trial from on the May results Conference. XXth, sharing Therapy for Cell this at be
PALLAS programs the our for pause remains example, already The clinical because was Phase PALLAS. fully brief a forward. study the for recruitments, Despite to key in XXXX, data early timing most move before from trial the of X pipeline top-line anticipated enrolled continue study
XXst, and XX-valent completed To look are we have a We just regarding March we also once our the results. to rescheduling picture studies pneumococcal waiting Day Investor have adult scheduled COVID-XX. the on clearer evolving forward previously of guidelines for
to message financial I So, XXXX see specifics our a of total give like a speak as to total in now, turn will Pfizer will guidance broad I over Pfizer it strength and the for and of Upjohn our and comments. resilience strong would Pfizer. his I review before you Frank, which more reaffirmed combined, I business. Frank regarding provide to
have XXXX was that other foreign on changes impact our incremental operational initial into three plan operations COVID-XX; R&D January, impact exchange during we and our made have have of the in guidance provided factors XXXX incorporated seen we we Since items in and our to the in to guidance: combat rates. investments and COVID-XX make projected terms P&L;
combating vaccine important the BioNTech, factor, us the which you of This this seen In we as science-based our million. $XXX rapidly first investment we COVID-XX our support with opportunities announce highly R&D already, for predominantly terms development by promising In have are is see in COVID-XX. initiative, XXXX moving projected increasing terms of in reflects forward. of investments collaboration
reduced second testing surgeries. to the patient office half within we factor, year. that recovery have the during our that we to impact will Regarding primarily with elective modeling changing the second negative expectation believe diagnostic markets due dynamics in are the economic and are the second the we likely analyzed later and activity new beginning reductions and starts, quarter, more see visits levels by in pre-COVID-XX in an But, year lower an overall of approach of healthcare levels driven
in many Obviously, with business of of we other a resilient and there our the as do business for the believe those but are still line economy. sight we clearer compared have model sectors uncertainties,
see pandemic. portfolio potential medicines, types comprises different from the we impact Our where COVID-XX of
have or new Some reliant Ibrance, such as generally reliant necessary, Vyndaqel continuing also some sterile utilization our increased patient or necessary and on crisis. starts, COVID-XX such more hospitals in products such as pandemic, certain are medically seeing and but the identified as of been still in Chantix used are of the other as injectable patients; Eliquis are on some And medicines more because medically surgeries.
doctor's of Also remember office. a of or our that self-injected oral center proportion large medicines that up not and is visit portfolio infusion made or to do a require
revenue pharmacy current of is which medicines delivery patients. enables direct addition, from Both for positive In derived are the majority to factors these our a environment. of portfolio in channels specialty
impact of we Given a COVID-XX. blended that anticipated
opportunity pace. oral a continuing an and may we provide are a with are continue time. during regular not drivers. dependent and offer Both expected Ibrance this are safety physicians. as patients for mature therapy new maintenance treatment generate to But on few larger which specifics Eliquis regarding their and appropriate leaders pandemic option such Medicines as growth also medicines, our they therefore starts. does to to me categories in well patient projecting the require with known revenue monitoring, an both alternative Attributes to impact COVID-XX Let very how are more more Eliquis, such noted profile,
As the the quarter, Ibrance in year. to expect second see patient would catch-up second of half a in also starts we expect we in while impact see for some Ibrance, the minimal to for
in is additional Vyndaqel new that of second dependent the the highly -- starts, office diagnosis, behind year on currently are patient good seeing We access. will a starts that drop prescribing the and diagnosis in But seeing that of office we and subsequent visits. a through patient the believe testing terms doctor's product and example and visit is diagnostic in also a the launched a we of currently. strong half this are anticipate resume requires product but process recently momentum patient not only
season. that awareness the in the anticipate infant Prevnar, be importance heightened take of Regarding in the a getting prior second of slowdown we temporary for vaccinations in resurgence second half will there will vaccinated anticipate quarter, to while the we place vaccinations next And believe of up year. we the in catch flu the adults, to
many in years, X market where to well-suited copay for the is by option category an patients. patients, current which products oral other and patient Xeljanz has more than has proportion payer environment. Xeljanz a a revenues for support. provides the large be Because broad in It its of been continuing also Xeljanz, driven for infusions, should access As are
We the in see year. impact expect again, expect the in temporarily to of we to half the patient recovery a see for Xeljanz in starts quarter. second new But, second
this well are used seeing highlight during as surgery, a seem which category. in generally be a we would impact physician. I Where which negative example, might with more BMP, with is for is is not a elective obvious. prescribed Chantix pronounced in would that And medicines products here two visit
we don't is will when portfolio, slowly see patients. normalization to as revenue And across sales So, the our but we lost physicians, revenue pandemic a be deferred these recouped looking and forever, mainly see physicians be that force and between and between as of the interactions eases.
impact terms a net we total operational of believe revenue in these should for As company XXXX. projections result, some factors anticipated be with the rate in negligible non-COVID combination related on that improvements our
also the indirect as for remaining the guidance both We our reflects spending reduced direct quarter, for the additional during and as first in identified indirect XXXX SI&A have efficiencies initiative. SI&A This reduction year. SI&A on reduced well some our
Lastly, dollar negatively and approximately of drives U.S. $X.XX. initial guidance exchange. $XXX revenues expected adjusted million the regarding in which has impacts our in by approximately January, an Since reduction per foreign strengthened, share earnings
to ranges our Bringing strength, projected guidance both, to underlying allow view on both,, observe the of this foreign initial projected R&D year exchange our this and in the million resilience maintain uncertain negative $XXX incremental this together lines. top in investment and of the bottom incremental impact our business times and all now, current breadth us
annual business our of following to long-term least the at fundamentals In And positioned revenue XXXX. growth expect remaining transaction, X% addition, the I to strong. Upjohn be of generate I through the compound business completion our see
even obviously expect to faster. EPS adjusted We grow
turn Frank? Now, it I will Frank. to over
